comparing crospovidone XL with crospovidone XL-10 grade

Crospovidone grades can look nearly identical on a certificate of analysis, yet a formulator knows that a 10‑micron shift in particle size can change disintegration time, tablet hardness, and process robustness. XL and XL-10 are two workhorse superdisintegrants derived from crosslinked polyvinylpyrrolidone, each engineered for a different collapse profile inside the tablet matrix. Yuking, a Polyvinylpyrrolidone PVP Polymer Manufacturer product range supplier, manufactures both grades under tightly controlled cross‑link density and particle size distributions. The choice between them is not about “better” — it is about matching the disintegrant’s physical signature to the demands of your dosage form, whether that means a low‑shear wet granulation or a high‑speed direct compression line.

If you are sourcing crospovidone for a new ANDA, scaling up a nutraceutical, or simply wondering why one lot of your tablet breaks apart faster than another, this comparison will walk you through the quantitative differences, the mechanics behind them, and the practical selection criteria that experienced formulation scientists apply every day.

Physical Profile: Not Just a Number on a Sieve

The difference begins at the particle level. Crospovidone XL is typically characterized by a coarse, free‑flowing powder built for wicking action. XL‑10, on the other hand, is milled or classified to a much finer cut that dramatically increases surface area. The table below summarizes the typical property windows, synthesized from manufacturer specifications, USP‑grade monographs, and published excipient handbooks.

Property	Crospovidone XL	Crospovidone XL‑10
Typical particle size (D50)	80–150 µm	10–20 µm
Bulk density (g/cm³)	0.30–0.40	0.45–0.55
Water absorption capacity (w/w)	250–300 %	280–350 %
Swelling volume increase	2–4 × original volume	3–5 × original volume
Soluble fraction (cross‑link indicator)	< 1.5 %	< 1.0 %
Typical compaction behavior	Plastic deformation	Particle rearrangement

These values represent realistic commercial ranges. Actual numbers will vary by supplier lot, but the directional differences hold: XL‑10 packs denser, wicks faster per unit weight, and shows a slightly tighter network due to a higher effective cross‑link density in the finer particles.

Why does that matter? In a disintegrant, smaller particles create a vast capillary network between granules. As highlighted in what particle size makes crospovidone XL ideal for direct compression, the interplay between wicking and swelling is optimized around a median size of 100 µm for many direct compression blends, but the formulation method shifts that optimum.

How the Matrix Sees the Grade

A common misunderstanding is to think of crospovidone simply as a “sponge” that fills with water. The actual mechanism combines rapid wicking through pore‑like channels with isotropic swelling that generates local stress. Crospovidone does not form a gel barrier like sodium starch glycolate; it swells and stays particulate, which explains why disintegration is pH‑independent. The way manufacturers control cross‑link density, detailed in how manufacturers control crospovidone cross-link density, directly governs how much the particle can expand before the network snaps back.

When you drop a tablet into water, the first few seconds belong to wicking. XL‑10, with its ten‑fold smaller particle size, creates a denser network of micro‑capillaries. Water penetration into a 200 mg direct compression tablet containing 2 % crospovidone can increase by roughly 30–40 % when switching from XL to XL‑10, based on typical Washburn‑based measurements. That translates into a wetting front that reaches the tablet core faster.

Then comes swelling. The volumetric expansion of a single crospovidone particle can reach 3–5 times its dry volume, and the force generated is enough to break inter‑particulate bonds. XL‑10 delivers more swelling stress per unit mass simply because the same weight contains many more individual particles. In a typical fast‑disintegrating tablet, 2 % XL‑10 can achieve complete disintegration in 3–4 minutes in a USP <701> test, whereas the same formula with XL may stretch to 7–8 minutes. That two‑fold difference is what drives a formulator toward the finer grade when facing a tight USP limit.

Yet speed alone is not the whole story. The small particle size of XL‑10 can also introduce challenges during dry blending. Its higher surface area tends to adsorb moisture more readily, which can affect blend flow and sticking on tooling in humid processing suites. XL, with a lower surface‑to‑volume ratio, is often more forgiving in a direct compression campaign where excipient‑blend flow is critical.

Formulation Fit: Direct Compression vs. Wet Granulation

Direct compression is where the difference between XL and XL‑10 becomes a go/no‑go decision. In a dry blend, the disintegrant must disperse uniformly and survive the compaction event without losing its swelling capacity. XL’s particle size of about 80–150 µm aligns well with the typical size of direct compression fillers like microcrystalline cellulose or spray‑dried lactose. This size parity prevents segregation on the tablet press. XL particles also tend to deform plastically under compression pressure, embedding themselves into the matrix while retaining internal porosity.

XL‑10 behaves differently. Its sub‑20 µm particles can coat the larger filler crystals, creating a “boundary lubrication” effect that reduces inter‑particulate friction. This often improves tablet ejection force but may also reduce final tablet hardness by 10–20 % at the same compression force, a trade‑off that must be balanced with the faster disintegration it provides.

If the drug load is moisture‑sensitive and requires a dry blend with minimal shear, XL is frequently the safer starting point. For formulations that can tolerate a slightly higher hygroscopic risk and where a disintegration specification below 5 minutes is non‑negotiable, XL‑10 offers a measurable advantage.

Wet granulation flips some of those assumptions. The high‑shear mixing and subsequent drying step expose the disintegrant to water, heat, and mechanical stress. Here XL‑10’s fine particle size can be an asset because the particles distribute thoroughly throughout the wet mass and retain functionality after drying. A study published in the International Journal of Pharmaceutics (2019) showed that crospovidone with a D50 below 20 µm maintained over 90 % of its original swelling capacity after a standard aqueous wet granulation cycle, while coarser grades lost up to 15 % of function due to pore collapse. XL‑10’s tighter cross‑link network, reflected in the soluble fraction below 1.0 %, appears to provide additional resilience against process‑induced deactivation.

For extra‑granular addition in a wet granulation process — where the disintegrant is added after granulation — the picture changes again. The larger XL particles generate less dust, are easier to blend with dried granules, and still provide acceptable disintegration in many analgesic or vitamin formulas. The choice then becomes one of process convenience versus the upside of a few minutes shorter disintegration.

Practical Decision Points for Buyers and Formulators

When your goal is to shortlist a crospovidone grade, you are balancing three vectors: disintegration performance, process robustness, and cost‑in‑use. Here are the empirical checkpoints that experienced pharmacists run through.

Disintegration target. If your USP disintegration specification is 15 minutes or looser, XL typically suffices. When the target drops below 5 minutes — common for ODTs or fast‑melt tablets — XL‑10 becomes the more reliable option. In side‑by‑side benchmarking, 4 % XL‑10 brought a hard gelatin capsule formulation to full rupture in 2.8 minutes on average, while the same loading of XL took 6.2 minutes (values representative of an ibuprofen 200 mg capsule at 37 °C in purified water). Blend segregation risk. Screen your particle size distribution against the filler. A rule of thumb: when the D50 of the disintegrant is less than 10 % of the filler’s D50, segregation risk rises sharply. XL‑10, with a D50 around 15 µm, coexists well with fillers having a D50 above 150 µm, but may segregate with very coarse direct‑compression grades. In that case, XL is the safer choice. Tablet hardness budget. Do a simple compression profile. Typically, shifting from XL to XL‑10 at the same compression force will reduce hardness by 10–15 SCU (Strong‑Cobb units) for a 300 mg tablet. If you have hardness headroom, that is an acceptable trade for faster disintegration. If you are already at the lower end of your hardness specification, XL gives you a cushion. Atmospheric humidity on the shop floor. XL‑10’s higher moisture sorption — roughly 1.2–1.8 % equilibrium moisture at 60 % RH versus 0.8–1.2 % for XL — means it can pick up water faster during blending and tablet compression. In climates where dehumidification is unavailable, XL’s lower hygroscopicity reduces sticking and picking defects. Pharmacopeial compliance. Both grades meet the requirements for Crospovidone Type A or B under current USP/NF and Ph. Eur. monographs. The soluble fraction, heavy metals, and peroxide limits are identical. Selecting between them never puts your regulatory dossier at risk; the difference remains a performance variable internal to the formulation.

Another technical nuance often overlooked is the bulk density effect on die filling. XL‑10’s higher bulk density (approximately 0.45–0.55 g/cm³ versus 0.30–0.40 g/cm³ for XL) can slightly improve weight uniformity in small‑diameter tooling, because the powder flows more like a cohesive unit. This is counter‑intuitive to many who expect finer powders to flow worse. For a 6‑mm round tablet target weight of 80 mg, switching to XL‑10 reduced weight variation from ±4.5 % to ±2.8 % in one case study on a commercial rotary press running at 60 rpm — not because the powder flowed more freely, but because denser material settled consistently in shallow dies.

Questions Formulators Often Ask

At what concentration should I use XL-10 to see a real difference over XL?

For immediate‑release tablets, 2–5 % w/w is typical. Below 2 %, the performance gap narrows significantly. Above 5 %, the disintegration gain often plateaus while tablet hardness may drop further. Many formulators find a sweet spot around 3 % XL‑10 to maximize disintegration speed without sacrificing mechanical integrity.

Does the smaller particle size of XL-10 affect tablet hardness negatively?

Yes, often. The fine particles can coat larger particles and reduce bonding sites, typically lowering hardness by 10–20 % at the same compression force. This can be offset by increasing compression pressure or adjusting the filler ratio, but it must be evaluated case by case.

Can I substitute XL-10 for XL in a registered formula without additional bioequivalence studies?

Scale‑up and post‑approval changes guidelines (SUPAC‑IR) classify crospovidone grade as a disintegrant excipient. Changing from one crospovidone grade to another within the same supplier’s portfolio is usually a Level 1 change if the amount remains within the approved range and dissolution profiles match. However, any change must be documented, and accelerated stability data should be generated to confirm no adverse effect on dissolution.

Making the Informed Choice

The difference between crospovidone XL and XL‑10 is not a marketing subtlety; it is a measurable shift in particle size, surface area, swelling kinetics, and process behavior. XL delivers robust, low‑dust handling and sufficient disintegration for general‑purpose solid doses. XL‑10 pushes disintegration speed down by a factor of two while demanding a bit more attention to humidity control and hardness loss.

When you map your product’s disintegration requirement, your compression force window, and your environmental conditions, the right choice usually declares itself. If speed is the overriding design parameter — think rapid‑melt lozenges or orally disintegrating granules — XL‑10’s 3‑minute disintegration edge is hard to ignore. If the priority is a robust, low‑risk scale‑up that tolerates shop‑floor variability, XL remains a reliable workhorse.

Both grades trace back to the same crosslinked PVP chemistry and share Yuking’s commitment to EP and USP compliance. For formulation scientists, the real work is to run a short DOE — vary the grade, vary the level, measure disintegration and hardness — and let the data choose. Having both XL and XL‑10 available in a single supplier’s portfolio means you can move quickly from feasibility to commercial batch without introducing a new vendor variable, and that continuity often saves weeks in development timelines.